Education
About Us
Working with TipRanks
Follow Us
Vicarious Surgical (RBOT)
NYSE:RBOT
RBOT Analyst Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RBOT Stock 12 Month Forecast
Average Price Target
―| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
―
Buy
―
Reiterated
11/13/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe think investors will like and support this plan. Reiterate Buy. The New CEO Stephen From, who replaced Adam Sachs as CEO this past summer, broke his near-term focus down to three main items: (1) reaching design freeze, (2) extending the company's runway through meaningful burn reduction and (3) strengthening how RBOT operates and communicates as a company. The first of these, reaching design freeze, is likely top of mind for most investors. To this end, RBOT intends to have a design-frozen, production-equivalent system with all the features and specifications required for commercialization by year-end 2026. From there, it can begin its regulatory V&V testing in 2027 from a "de-risked" position, having already done continuous verification and usability testing.
BTIG
―
Hold
―
Reiterated
11/13/25
Piper Sandler
$7
Hold
160.22%
Upside
Reiterated
08/13/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
―
Buy
―
Reiterated
11/13/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe think investors will like and support this plan. Reiterate Buy. The New CEO Stephen From, who replaced Adam Sachs as CEO this past summer, broke his near-term focus down to three main items: (1) reaching design freeze, (2) extending the company's runway through meaningful burn reduction and (3) strengthening how RBOT operates and communicates as a company. The first of these, reaching design freeze, is likely top of mind for most investors. To this end, RBOT intends to have a design-frozen, production-equivalent system with all the features and specifications required for commercialization by year-end 2026. From there, it can begin its regulatory V&V testing in 2027 from a "de-risked" position, having already done continuous verification and usability testing.
BTIG
―
Hold
―
Reiterated
11/13/25
Piper Sandler
$7
Hold
160.22%
Upside
Reiterated
08/13/25
Best Analysts Covering Vicarious Surgical
1 Month
xxx
Success Rate
4/10 ratings generated profit
Average Return
-3.30%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -3.30% per trade.
3 Months
xxx
Success Rate
4/10 ratings generated profit
Average Return
+7.14%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +7.14% per trade.
1 Year
Success Rate
3/10 ratings generated profit
Average Return
-24.51%
reiterated a buy rating 16 days ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -24.51% per trade.
2 Years
xxx
Success Rate
0/10 ratings generated profit
Average Return
-66.32%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -66.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RBOT Analyst Recommendation Trends
Rating
Apr 25
May 25
Jul 25
Aug 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
1
2
1
2
2
Hold
4
3
2
4
4
Sell
4
4
2
0
0
Strong Sell
0
0
0
0
0
total
9
9
5
6
6
Each month's total comprises the sum of three months' worth of ratings.
RBOT Financial Forecast
RBOT Stock Forecast FAQ
What is RBOT’s average 12-month price target, according to analysts?
Currently, no data Available
What is RBOT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for RBOT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RBOT a Buy, Sell or Hold?
Vicarious Surgical has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
What is Vicarious Surgical’s price target?
Currently, no data Available
What do analysts say about Vicarious Surgical?
Vicarious Surgical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of RBOT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.